The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Treatment of Refractory and Relapsed Acute Myelogenous Leukemia With Combination Chemotherapy Plus the Multidrug Resistance Modulator PSC 833 (Valspodar)
Abstract
A potential mechanism of chemotherapy resistance in acute myeloid leukemia (AML) is the multidrug resistance (MDR-1) gene product P-glycoprotein (P-gp), which is often overexpressed in myeloblasts from refractory or relapsed AML. In a multicenter phase II clinical trial, 37 patients with these poor risk forms of AML were treated with PSC 833 (Valspodar; Novartis Pharmaceutical Corporation, East Hanover, NJ), a potent inhibitor of the MDR-1 efflux pump, plus mitoxantrone, etoposide, and cytarabine (PSC-MEC). Pharmacokinetic (PK) interactions of etoposide and mitoxantrone with PSC were anticipated, measured in comparison with historical controls without PSC, and showed a 57% decrease in etoposide clearance (P = .001) and a 1.8-fold longer beta half-life for mitoxantrone in plasma (P < .05). The doses of mitoxantrone and etoposide were substantially reduced to compensate for these interactions and clinical toxicity and in Cohort II were well tolerated at dose levels of 4 mg/m2mitoxantrone, 40 mg/m2 etoposide, and 1 g/m2 C daily for 5 days. Overall, postchemotherapy marrow hypoplasia was achieved in 33 patients. Twelve patients (32%) achieved complete remission, four achieved partial remission, and 21 failed therapy. The PK observations correlated with enhanced toxicity. The probability of an infectious early death was 36% (4 of 11) in patients with high PK parameters for either drug versus 5% (1 of 20) in those with lower PK parameters (P = .04). P-gp function was assessed in 19 patients using rhodamine-123 efflux and its inhibition by PSC. The median percentage of blasts expressing P-gp was increased (49%) for leukemic cells with PSC-inhibitable rhodamine efflux compared with 17% in cases lacking PSC-inhibitable efflux (P = .004). PSC-MEC was relatively well tolerated in these patients with poor-risk AML, and had encouraging antileukemic effects. The Eastern Cooperative Oncology Group is currently testing this regimen versus standard MEC chemotherapy in a phase III trial, E2995, in a similar patient population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line
Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V., & Deeley, R. G. (1992) · Science · doi:10.1126/science.1360704 · Cited by 3,037
Research works printed but not linked: 73
- Velu, 1988, Daunorubicin in patients with relapsed and refractory acute non-lymphocytic leukemia previously treated with anthracycline., Am J Hematol, 27, 224, 10.1002/ajh.2830270315 · DOI
- Capizzi, 1984, Treatment of poor risk acute leukemia with sequential high dose Ara-C and asparaginase., Blood, 63, 694
- Herzig, 1985, High dose cytarabine for reinduction of acute non lymphoblastic leukemia., J Clin Oncol, 3, 992, 10.1200/JCO.1985.3.7.992 · doi:10.1200/jco.1985.3.7.992
- List, 1993, Multidrug resistance: Clinical relevance in acute leukemia., Oncology, 7, 23
- Gottesman, 1993, Biochemistry of multidrug resistance mediated by the multidrug transporter., Annu Rev Bioch, 62, 385, 10.1146/annurev.bi.62.070193.002125 · DOI · Paper page
- Sikic, 1993, Modulation of multi drug resistance: At the threshold., J Clin Oncol, 11, 1629, 10.1200/JCO.1993.11.9.1629 · DOI · Paper page
- Campos, 1992, Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis., Blood, 79, 473, 10.1182/blood.V79.2.473.473 · DOI · Paper page
- Marie, 1991, Multidrug resistance (mdr1) gene expression in adult acute leukemias: Correlations with treatment outcome and in vitro drug sensitivity., Blood, 78, 586, 10.1182/blood.V78.3.586.586 · DOI · Paper page
- List, 1991, Expression of the multidrug resistance gene product (P-glycoprotein) in myelodysplasia is associated with a stem cell phenotype., Br J Haematol, 78, 28, 10.1111/j.1365-2141.1991.tb04378.x · doi:10.1111/j.1365-2141.1991.tb04378.x
- Boekhorst, 1993, Predominance of functional multidrug resistance (MDR-1) phenotype in CD34+ acute myeloid leukemia cells., Blood, 82, 3157, 10.1182/blood.V82.10.3157.3157 · DOI
- Herweijor, 1990, Expression of mdr1 and mdr3 multidrug resistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation by cyclosporine., J Natl Cancer Inst, 82, 1133, 10.1093/jnci/82.13.1133 · DOI · Paper page
- Nooter, 1990, Overexpression of the mdr1 gene in blast cells from patients with acute myelocytic leukemia is associated with stimulation of drug accumulation that can be restored by cyclosporin-A., Int J Cancer, 45, 263, 10.1002/ijc.2910450210 · doi:10.1002/ijc.2910450210
- Pirker, 1991, MDR1 gene expression and treatment outcome in acute myeloid leukemia., J Natl Cancer Inst, 83, 708, 10.1093/jnci/83.10.708 · DOI · Paper page
- Solary, 1992, Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia., J Clin Oncol, 10, 1730, 10.1200/JCO.1992.10.11.1730 · doi:10.1200/jco.1992.10.11.1730
- Berman, 1995, Phase 1 trial of high dose tamoxifen as a modulator of drug resistance in combination with daunorubicin in patients with relapsed or refractory AML., Leukemia, 9, 1631
- List, 1993, Phase I/II trial of cyclosporin as a chemotherapy-resistance modifier in acute leukemia., J Clin Oncol, 11, 1652, 10.1200/JCO.1993.11.9.1652 · DOI · Paper page
- Solary, 1996, Combination of quinine as a potential reversing agent with mitroxantrone and cytarabine for the treatment of acute leukemias. A randomized multicenter study., Blood, 88, 1198, 10.1182/blood.V88.4.1198.bloodjournal8841198 · DOI
- Fisher, 1995, Clinical studies with modulators of multi drug resistance
- Twentyman, 1991, Resistance modification by PSC 833, a novel non-immunosuppressive cyclosporin. A., Eur J Cancer, 27, 1639, 10.1016/0277-5379(91)90435-G · DOI · Paper page
- Boesh, 1991, In vivo circumvention of P-glycoprotein-mediated multi drug resistance of tumor cells with SDZ PSC833., Cancer Res, 51, 4226
- Bennett, 1985, Proposed criteria for the classification of acute myeloid leukemia. A report of the French, America and British cooperative group., Ann Intern Med, 103, 620, 10.7326/0003-4819-103-4-620 · DOI · Paper page
- Amadori, 1991, Mitoxantrone, etoposide and intermediate-dose cytarabine: An effective and tolerable regimen for the treatment of refractory acute myeloid leukemia., J Clin Oncol, 9, 1210, 10.1200/JCO.1991.9.7.1210 · doi:10.1200/jco.1991.9.7.1210
- Fisher, 1996, Pharmacological considerations in the modulation of multi drug resistance., Eur J Cancer, 32A, 1082, 10.1016/0959-8049(96)00111-6 · DOI
- Oken, 1982, Toxicity and response criteria of the Eastern Cooperative Oncology Group., Am J Clin Oncol, 5, 649, 10.1097/00000421-198212000-00014 · DOI · Paper page
- Cheson, 1990, Report of the National Cancer Institute sponsored workshop on definition of diagnoses and response in acute myeloid leukemia., J Clin Oncol, 8, 813, 10.1200/JCO.1990.8.5.813 · DOI · Paper page
- Preisler, 1994, Regrowth Resistance in leukemias and lymphomas. The need for a new system to classify system failures and new approaches for treatment., Leuk Res, 18, 149, 10.1016/0145-2126(94)90109-0 · doi:10.1016/0145-2126(94)90109-0
- Paietta, 1998, Acute myeloid leukemia expressing the leucocyte integrin CD11b a new leukemic syndrome with poor prognosis: Result of an ECOG database analysis., Br J Haematol, 100, 265, 10.1046/j.1365-2141.1998.00561.x · doi:10.1046/j.1365-2141.1998.00561.x
- Paietta, 1994, Significantly lower P-glycoprotein expression in acute promyelocytic leukemia than in other types of AML. Immunological, molecular and functional analyses., Leukemia, 8, 968
- Paietta, 1995, Modulation of multidrug resistance in de novo adult acute myeloid leukemia. Variable efficacy of reverting agents in vitro., Blood Rev, 9, 47, 10.1016/0268-960X(95)90039-X · doi:10.1016/0268-960x(95)90039-x
- Paietta, 1997, The prognostic significance of immune profiles in adult acute myeloid leukemia varies with age: A comparative analysis of the Eastern Cooperative Oncology Group (ECOG) database., Proc Am Soc Clin Oncol, 16, 5a
- Lum, 1992, Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a Phase I trial to modulate MDR., J Clin Oncol, 10, 1635, 10.1200/JCO.1992.10.10.1635 · DOI · Paper page
- Peng, 1982, Improved high-performance liquid chromatography of the new antineoplastic agents bisantrene and mitoxantrone., J Chromatogr, 233, 235, 10.1016/S0378-4347(00)81750-8 · doi:10.1016/s0378-4347(00)81750-8
- Attal, 1994, Escalating doses of mitoxantrone with high dose cyclophosphamide, carmustine and etoposide in patients with lymphoma undergoing autologous bone marrow transplantation., J Clin Oncol, 12, 141, 10.1200/JCO.1994.12.1.141 · doi:10.1200/jco.1994.12.1.141
- Mehta, 1984, Exact significance testing to establish treatment equivalence with ordered categorical data., Biometrics, 45, 819, 10.2307/2530927 · DOI · Paper page
- Kaplan, 1958, Nonparametric estimation from incomplete observations., J Am Stat Assoc, 53, 457, 10.1080/01621459.1958.10501452 · DOI · Paper page
- Shapiro, 1972, An approximate analysis of variance test for normality., J Am Stat Assoc, 67, 215, 10.1080/01621459.1972.10481232 · DOI · Paper page
- Brown, 1977, Statistics: A Biomedical Introduction., 174, 10.1002/9780470316474 · DOI · Paper page
- Yahanda, 1992, Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance., J Clin Oncol, 10, 1624, 10.1200/JCO.1992.10.10.1624 · DOI · Paper page
- Boote, 1996, Phase I study of etoposide with SDZ PSC833 as a modulator of multi-drug resistance in patients with cancer., J Clin Oncol, 14, 610, 10.1200/JCO.1996.14.2.610 · DOI · Paper page
- Stiff, 1994, Phase I clinical and pharmacokinetic study of high dose mitoxantrone combined with carboplatin, cyclophosphamide and autologous bone marrow rescue. High response rate for refractory ovarian cancer., J Clin Oncol, 12, 176, 10.1200/JCO.1994.12.1.176 · doi:10.1200/jco.1994.12.1.176
- Estey, 1996, A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory AML., Blood, 88, 756, 10.1182/blood.V88.2.756.bloodjournal882756 · DOI
- Paciucci, 1987, Mitoxantrone and Ara-C in previously treated patients with AML., Leukemia, 1, 565
- Hiddemann, 1987, High dose cytosine arabinoside and mitoxantrone: A highly effective regimen in refractory acute myeloid leukemia., Blood, 69, 744, 10.1182/blood.V69.3.744.744 · doi:10.1182/blood.v69.3.744.744
- Rowe, 1994, Treatment of relapsed and refractory AML with mitoxantrone and etoposide; a study of the ECOG, 235, 10.1007/978-3-642-78350-0_40 · doi:10.1007/978-3-642-78350-0_40
- Geller, 1996, Use of cytokines in the treatment of acute myelomonocytic leukemia: A critical review., J Clin Oncol, 14, 1371, 10.1200/JCO.1996.14.4.1371 · doi:10.1200/jco.1996.14.4.1371
- Rowe, 1995, A randomized placebo controlled phase III study of GM-CSF in elderly patients (>55 to 70 yrs. of age) with AML. A study of ECOG., Blood, 86, 457, 10.1182/blood.V86.2.457.bloodjournal862457 · DOI · Paper page
- Tallman, 1996, Mitoxantrone, etoposide and cytosine arabinoside plus cyclosporine in patients with relapsed or refractory acute myeloid leukemia (AML). An Eastern Cooperative Oncology Group (ECOG) pilot study., Blood, 88, 216a
- Kornblau, 1997, Phase 1 study of Mitoxantrone plus Etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory AML., J Clin Oncol, 15, 1796, 10.1200/JCO.1997.15.5.1796 · DOI
- Keller, 1992, Pharmacologic interactions between the resistance modifying cyclosporine SDZ PSC833 and etoposide enhance in vivo cytostatic activity and toxicity., Int J Cancer, 51, 433, 10.1002/ijc.2910510316 · DOI
- Keller, 1992, SDZ PSC 833, a non-immunosuppressive cyclosporine and its potency in overcoming P-glycoprotein-mediated multidrug resistance of murine leukemia., Int J Cancer, 50, 593, 10.1002/ijc.2910500418 · doi:10.1002/ijc.2910500418
- Arceci, 1993, Clinical significance of P-glycoprotein in multidrug resistance malignancies., Blood, 81, 2215, 10.1182/blood.V81.9.2215.2215 · DOI · Paper page
- Sato, 1990, MDR1 transcripts levels as an indication of resistant disease in acute myelogenous leukemia., Br J Haematol, 75, 340, 10.1111/j.1365-2141.1990.tb04346.x · doi:10.1111/j.1365-2141.1990.tb04346.x
- Leith, 1997, Acute myeloid leukemia in the elderly: Assessment of MDR-1 and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A SWOG study., Blood, 89, 3323, 10.1182/blood.V89.9.3323 · DOI · Paper page
- Leith, 1997, Frequency and clinical significance of expression of the multidrug resistance proteins MDR1, MRP1 and LRP in acute myeloid leukemia patients less than 65 years old. A Southwest Oncology Group study., Blood, 90, 389a
- Paietta, 1997, Classical multi drug resistance in acute myeloid leukemia., Med Oncol, 14, 53, 10.1007/BF02990947 · doi:10.1007/bf02990947
- Beck, 1996, Methods to detect P-glycoprotein associated with multidrug resistance in patients’ tumors. Consensus recommendations., Cancer Res, 56, 3010
- Paietta, 1995, Modulation of multidrug resistance in de novo adult acute myeloid leukemia., Blood Rev, 9, 47, 10.1016/0268-960X(95)90039-X · doi:10.1016/0268-960x(95)90039-x
- Wattel, 1996, Quinine improves results of intensive chemotherapy in myelodysplastic syndromes (MDS) expressing P-glycoprotein., Blood, 88, 455a
- List, 1996, Modulation of anthracycline resistance in poor risk acute myeloid leukemia with SDZ PSC-833: Results of a phase I/II multicenter study., Blood, 88, 292a
- Visani, 1997, A Phase I dose finding study of PSC 833, a novel MDR reversing agent with mitoxantrone, etoposide and cytarabine., Blood, 90, 566a
- Chen, 1990, Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein., J Biol Chem, 265, 10073, 10.1016/S0021-9258(19)38781-2 · DOI · Paper page
- Scheper, 1993, Overexpression of aM110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance., Cancer Res, 53, 1475
- Leith, 1995, Correlation of Multidrug Resistance (MDR-1) protein expression with functional dye/drug efflux in AML by multiparameter flow cytometry: Identification of discordant MDR−/Efflux+ and MDR-1+/Efflux− cases., Blood, 86, 2329, 10.1182/blood.V86.6.2329.bloodjournal8662329 · DOI · Paper page
- Filipits, 1998, Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia., Blood, 91, 1508, 10.1182/blood.V91.5.1508 · DOI
- List, 1996, Overexpression of the major vault transporter protein, lung resistance protein predicts treatment outcome in acute myeloid leukemia., Blood, 87, 2464, 10.1182/blood.V87.6.2464.bloodjournal8762464 · DOI · Paper page
- Schneider, 1995, Increased expression of the multidrug resistance associated protein gene in relapsed acute leukemia., Blood, 85, 186, 10.1182/blood.V85.1.186.bloodjournal851186 · doi:10.1182/blood.v85.1.186.bloodjournal851186
- Lorico, 1996, Double knockout of the MRP gene leads to increased drug sensitivity in vitro., Cancer Res, 56, 5351
- List, 1997, Non-P-glycoprotein drug export mechanisms of multidrug resistance., Semin Hematol, 34, 20
- Reed, 1997, Bcl-2 family proteins: Regulators of apoptosis and chemoresistance in hematologic malignancies., Semin Hematol, 34, 9
- Valkov, 1997, Drug resistance to DNA topoisomerase I and II inhibitors in human leukemia, lymphoma and multiple myeloma., Semin Hematol, 34, 48
- Beketic-Oreskovic, 1995, Decreased mutation rate for doxorubicin resistance and suppression of mdr 1 gene activation by PSC 833., J Natl Cancer Inst, 87, 1593, 10.1093/jnci/87.21.1593 · DOI
- Sikic, 1997, Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein., Cancer Chemother Pharmacol, 40, S13, 10.1007/s002800051055 · DOI · Paper page
- Futscher, 1996, Verapamil suppresses the emergence of P-glycoprotein-mediated multi-drug resistance., Int J Cancer, 66, 520, 10.1002/(SICI)1097-0215(19960516)66:4<520::AID-IJC16>3.0.CO;2-B · doi:10.1002/(sici)1097-0215(19960516)66:4<520::aid-ijc16>3.0.co;2-b
Cited by
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
Mechanisms of Cancer Drug Resistance
Gottesman, M. M. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.103929 · Cited by 2,643
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Thomas, H., & Coley, H. M. (2003) · Cancer Control · doi:10.1177/107327480301000207 · Cited by 931
Multidrug resistance transporters and modulation
Tan, B., Piwnica-Worms, D., & Ratner, L. (2000) · Current Opinion in Oncology · doi:10.1097/00001622-200009000-00011 · Cited by 384
Metadata
- Authors
- Advani, R., Saba, H. I., Tallman, M. S., Rowe, J. M., Wiernik, P. H., Ramek, J., Dugan, K., Lum, B., Villena, J., Davis, E., Paietta, E., Litchman, M., Sikic, B. I., & Greenberg, P. L.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 1999-02-01
- Volume
- 93
- Issue
- 3
- Pages
- 787-795
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W1249439018
- Cited by
- 158
- References
- 1
- FWCI
- 8.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of Refractory and Relapsed Acute Myelogenous Leukemia With Combination Chemotherapy Plus the Multidrug Resistance Modulator PSC 833 (Valspodar). https://app.cochat.ai/papers/10.1182/blood.v93.3.787
- The paper
- Advani, R., Saba, H. I., Tallman, M. S., Rowe, J. M., Wiernik, P. H., Ramek, J., Dugan, K., Lum, B., Villena, J., Davis, E., Paietta, E., Litchman, M., Sikic, B. I., & Greenberg, P. L. (1999). Treatment of Refractory and Relapsed Acute Myelogenous Leukemia With Combination Chemotherapy Plus the Multidrug Resistance Modulator PSC 833 (Valspodar). Blood. https://doi.org/10.1182/blood.v93.3.787
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.